Sionna Therapeutics, Inc. (SION) Stock Price & Analysis

Sionna Therapeutics, Inc. (SION) rose 0.00% to USD 45.7 as of July 26, 2026 at 05:57 UTC, according to Nexqual real-time market data.

SION last closed at USD 45.7; the session ranged USD 43.41–46.4 on volume of 647,306 shares. Market capitalization is —, with a 52-week range of USD 16.38–51.57 (NGM). Source: Nexqual, July 26, 2026 at 05:57 UTC.

Key Statistics (as of July 26, 2026 at 05:57 UTC)

Technical Analysis (SION)

Nexqual's technical model rates SION "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 05:57 UTC.

From Sionna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• We have developed a broad patent estate and expect to expand and protect our proprietary know-how and intellectual property.
• While we have prioritized development of a proprietary dual combination, we believe both development pathways offer attractive commercial opportunities. 10 Table of Contents Figure 1 Our Pipeline The following table summarizes our clinical stage pipeline: Figure 2 Our proprietary portfolio is anchored by our NBD1 stabilizers and our complementary modulators.
• We believe the model allows us to determine the target exposure needed to achieve a desired level of clinical activity, such as the level of improvement in a patient's forced expiratory volume in one second ("FEV 1" ), a measure of lung function, and sweat chloride level, the clinical biomarker of CFTR function.
• Our Approach and Leveraging the CFHBE Model Our programs leverage an industry standard, clinically predictive CFHBE model to measure CFTR protein function in vitro.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 05:57 UTC. This page is informational and not investment advice.